FY2024 Earnings Estimate for Vericel Issued By HC Wainwright

Vericel Co. (NASDAQ:VCEL - Free Report) - Research analysts at HC Wainwright reduced their FY2024 EPS estimates for shares of Vericel in a research note issued to investors on Wednesday, January 15th. HC Wainwright analyst S. Ramakanth now anticipates that the biotechnology company will post earnings per share of $0.16 for the year, down from their prior estimate of $0.21. HC Wainwright has a "Buy" rating and a $60.00 price objective on the stock. The consensus estimate for Vericel's current full-year earnings is $0.13 per share. HC Wainwright also issued estimates for Vericel's Q4 2024 earnings at $0.33 EPS, Q1 2025 earnings at $0.03 EPS, Q2 2025 earnings at $0.00 EPS and FY2029 earnings at $2.80 EPS.

Vericel (NASDAQ:VCEL - Get Free Report) last announced its quarterly earnings results on Thursday, November 7th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.05) by $0.03. Vericel had a net margin of 1.56% and a return on equity of 1.48%. The firm had revenue of $57.91 million for the quarter, compared to the consensus estimate of $55.32 million.

Several other brokerages have also commented on VCEL. Stephens reaffirmed an "overweight" rating and issued a $65.00 price objective on shares of Vericel in a report on Wednesday. StockNews.com upgraded Vericel from a "sell" rating to a "hold" rating in a research note on Tuesday, December 24th. Truist Financial increased their price objective on shares of Vericel from $61.00 to $67.00 and gave the stock a "buy" rating in a research note on Wednesday, December 18th. BTIG Research boosted their target price on shares of Vericel from $56.00 to $66.00 and gave the company a "buy" rating in a research report on Tuesday, November 26th. Finally, Canaccord Genuity Group reiterated a "buy" rating and issued a $60.00 price target on shares of Vericel in a research report on Tuesday, November 19th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $62.14.

Vericel Trading Down 2.1 %

NASDAQ:VCEL traded down $1.20 during trading hours on Thursday, reaching $56.35. The company had a trading volume of 425,132 shares, compared to its average volume of 500,973. The firm's 50 day moving average price is $56.80 and its 200-day moving average price is $49.89. The firm has a market cap of $2.78 billion, a price-to-earnings ratio of 939.32 and a beta of 1.72. Vericel has a 52 week low of $37.35 and a 52 week high of $61.49.

Hedge Funds Weigh In On Vericel

Several institutional investors have recently bought and sold shares of VCEL. International Assets Investment Management LLC increased its holdings in shares of Vericel by 4,126.7% in the third quarter. International Assets Investment Management LLC now owns 634 shares of the biotechnology company's stock worth $27,000 after purchasing an additional 619 shares during the last quarter. Farther Finance Advisors LLC increased its stake in Vericel by 48.1% in the 3rd quarter. Farther Finance Advisors LLC now owns 1,247 shares of the biotechnology company's stock worth $53,000 after acquiring an additional 405 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its stake in Vericel by 22.2% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,773 shares of the biotechnology company's stock worth $77,000 after acquiring an additional 322 shares during the last quarter. Meeder Asset Management Inc. purchased a new stake in shares of Vericel during the 3rd quarter worth approximately $92,000. Finally, Quantbot Technologies LP bought a new position in shares of Vericel during the 3rd quarter valued at approximately $146,000.

Insiders Place Their Bets

In related news, Director Robert L. Md Zerbe sold 2,500 shares of the stock in a transaction dated Friday, November 22nd. The stock was sold at an average price of $60.00, for a total transaction of $150,000.00. Following the completion of the sale, the director now owns 26,595 shares in the company, valued at approximately $1,595,700. This trade represents a 8.59 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Paul K. Wotton sold 2,600 shares of Vericel stock in a transaction that occurred on Wednesday, December 4th. The shares were sold at an average price of $58.72, for a total value of $152,672.00. Following the sale, the director now directly owns 27,402 shares in the company, valued at $1,609,045.44. This trade represents a 8.67 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 15,100 shares of company stock worth $889,872. Company insiders own 7.20% of the company's stock.

About Vericel

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.